Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AV-380 in metastatic cancer patients with cachexia
NCT05865535Phase 1Recruiting
- Sponsor
- AVEO Oncology
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilogrotug in cachexia, sponsored by AVEO Oncology. Primary endpoints: Adverse Events, Toxicity up to 4 months and 1 more. Started Jun 2023; status: recruiting.
02
Drugs
rilogrotug
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT05865535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05865535.